Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The progression of chronic myelogenous leukemia (CML) to blast crisis is supported by self-renewing leukemic stem cells. In normal mouse hematopoietic stem cells, the process of self-renewal involves the beta-catenin-signaling pathway. We investigated whether leukemic stem cells in CML also use the beta-catenin pathway for self-renewal. METHODS: We used fluorescence-activated cell sorting to isolate hematopoietic stem cells, common myeloid progenitors, granulocyte-macrophage progenitors, and megakaryocyte-erythroid progenitors from marrow during several phases of CML and from normal marrow. BCR-ABL, beta-catenin, and LEF-1 transcripts were compared by means of a quantitative reverse-transcriptase-polymerase-chain-reaction assay in normal and CML hematopoietic stem cells and granulocyte-macrophage progenitors. Confocal fluorescence microscopy and a lymphoid enhancer factor/T-cell factor reporter assay were used to detect nuclear beta-catenin in these cells. In vitro replating assays were used to identify self-renewing cells as candidate leukemic stem cells, and the dependence of self-renewal on beta-catenin activation was tested by lentiviral transduction of hematopoietic progenitors with axin, an inhibitor of the beta-catenin pathway. RESULTS: The granulocyte-macrophage progenitor pool from patients with CML in blast crisis and imatinib-resistant CML was expanded, expressed BCR-ABL, and had elevated levels of nuclear beta-catenin as compared with the levels in progenitors from normal marrow. Unlike normal granulocyte-macrophage progenitors, CML granulocyte-macrophage progenitors formed self-renewing, replatable myeloid colonies, and in vitro self-renewal capacity was reduced by enforced expression of axin. CONCLUSIONS: Activation of beta-catenin in CML granulocyte-macrophage progenitors appears to enhance the self-renewal activity and leukemic potential of these cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both myelodysplastic syndrome (Pang et al., 2013) and acute and chronic myelogenous leukemias begin with nonlethal mutations in the HSC pool, often leading to successful expansion of mutant HSC clones at the expense of normal HSC, and which progress eventually to leukemia (Corces-Zimmerman et al., 2014; Jamieson et al., 2004; Jan et al., 2012)”
From Quiescent Hematopoietic Stem Cells Accumulate DNA Damage during Aging that Is Repaired upon Entry into Cell Cycle (2014) · cites this paper as Jamieson et al., 2004
In the citing paper
“Although CML is considered a HSC-initiated disease, studies indicate that granulocyte-monocyte progenitors isolated from advanced-phase CML patients reacquire self-renewal properties and therefore may also serve as LSC.6”
From Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo (2010) · cites this paper as [6]
In the citing paper
“Although CML is considered a HSC-initiated disease, studies indicate that granulocyte-monocyte progenitors isolated from advanced-phase CML patients reacquire self-renewal properties and therefore may also serve as LSC.6”
From Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo (2010) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Self-citationConstitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Self-citationA role for Wnt signalling in self-renewal of haematopoietic stem cells
Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R., & Weissman, I. L. (2003) · Nature · doi:10.1038/nature01593 · Cited by 2,159
Self-citation
Cited by
Items 601–700 of 1,000
Mak, D. H. F., Wang, R.-Y., Schober, W. D., Konopleva, M. Y., Cortes, J. E., Kantarjian, H. M., Andreeff, M., & Carter, B. Z. (2011) · Leukemia · doi:10.1038/leu.2011.285 · Cited by 44
Giotopoulos, G., van der Weyden, L., Osaki, H., Rust, A. G., Gallipoli, P., Meduri, E., Horton, S. J., Chan, W.-I., Foster, D., Prinjha, R. K., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141661 · Cited by 50
“CML stem cells appear relatively resistant to the effects of TKIs (Copland et al., 2006; Jørgensen et al., 2007; Konig et al., 2008) such that, in the majority of patients, CML is controlled rather than cured.”
BackgroundSurvival regulation of leukemia stem cells
Hu, Y., & Li, S. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2108-7 · Cited by 46
García‐García, A., Klein, T., Born, G., Hilpert, M., Scherberich, A., Lengerke, C., Skoda, R. C., Bourgine, P. E., & Martín, I. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114227118 · Cited by 43
“Acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN) are clonal hematopoietic malignancies characterized by overproduction of neoplastic hematopoietic cells (11, 12), which evolve and hijack BM microenvironments to create supportive niches for leukemic stem cells (13–19).”
BackgroundCancer stem cells in leukemia, recent advances
Zou, G.-M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21140 · Cited by 47
“The finding that AML stem cells require interaction with a niche to maintain their stem cell properties provides a therapeutic strategy to eliminate quiescent AML stem cells (Jin et al., 2006).”
BackgroundThe Emerging Picture of Human Breast Cancer as a Stem Cell-based Disease
Cobaleda, C., Cruz, J. J., González‐Sarmiento, R., Sánchez-García, I., & Pérez‐Losada, J. (2008) · Stem Cell Reviews and Reports · doi:10.1007/s12015-008-9012-6 · Cited by 47
“In fact, in other systems, like some types of leukemia, it has been proposed that progenitor cells might become a de novo CSCs by the acquisition of stem cell properties [63–66].”
BackgroundWithey, J., Marley, S. B., Kaeda, J., Harvey, A., Crompton, M. R., & Gordon, M. Y. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05468.x · Cited by 41
“Using colony replating to quantify the proliferation/self-renewal of myeloid progenitors we, and others (Jamieson et al, 2004), have determined that CML progenitor amplification is a key contributor to pathogenic myeloid expansion.”
MethodCancer, stem cells, and oncolytic viruses
Ribacka, C., Pesonen, S. A., & Hemminki, A. (2008) · Annals of Medicine · doi:10.1080/07853890802021342 · Cited by 50
“Alternatively, cancer stem cells may arise from progenitor cells that attain the ability of selfperpetuation through alterations in major signaling pathways like the Wnt pathway (28).”
BackgroundStem-Cell Aging and Pathways to Precancer Evolution
Jamieson, C. H. M., & Weissman, I. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2304431 · Cited by 42
Cell Fusion Hypothesis of the Cancer Stem Cell
Lü, X., & Kang, Y. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-0782-5_6 · Cited by 41
Brot, M. D., Rocha, R. M., Soares, F. A., & Gobbi, H. (2012) · Pathology · doi:10.1097/pat.0b013e3283534bcb · Cited by 39
“It is probable that CSCs have a phenotype defined by the cell of origin (stem cells or early progenitor cells) and by the oncogenic events that contribute to transformation.(25) A candidate marker of CSCs is aldehyde dehydrogenase 1 (ALDH1), an enzyme responsible for oxidising intracellular aldehydes and crucial durin…”
BackgroundStem cell origin of myelodysplastic syndromes
Elias, H. K., Schinke, C., Bhattacharyya, S., Will, B., Verma, A. K., & Steidl, U. G. (2013) · Oncogene · doi:10.1038/onc.2013.520 · Cited by 42
Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia
Lu, J., Ma, Y., Kong, N., Alipio, Z., Gao, C., Krause, D. S., Silberstein, L. E., & Chai, L. (2011) · Leukemia · doi:10.1038/leu.2011.65 · Cited by 40
Affer, M., Dao, S., Liu, C., Olshen, A. B., Mo, Q., Viale, A. J., Lambek, C. L., Marr, T. G., & Clarkson, B. (2011) · Journal of Oncology · doi:10.1155/2011/798592 · Cited by 41
BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
Sharma, N. D., Magistroni, V., Piazza, R., Citterio, S., Mezzatesta, C., Khandelwal, P., Pirola, A., & Gambacorti-Passerini, C. B. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0407-0 · Cited by 45
“(GMPs) and this mechanism is conserved in healthy donors and in CP-CML [39].”
BackgroundInfluentialBCR/ABL Expression of Myeloid Progenitors Increases β1-Integrin Mediated Adhesion to Stromal Cells
Fierro, F. A., Taubenberger, A. V., Puech, P., Ehninger, G., Bornhäuser, M., Müller, D. J., & Illmer, T. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.01.085 · Cited by 40
Implications of Cancer Stem Cells In the Treatment of Cancer
Pan, C.-X., Zhu, W. P., & Cheng, L. (2006) · Future Oncology · doi:10.2217/14796694.2.6.723 · Cited by 42
“In CML, leukemic granulocyte–macrophage progenitors, unlike the normal granulocyte–macrophage progenitors, possessed the capability of self-renewal and formation of myloid colonies, the two characteristics of stem cells [23].”
BackgroundFirst among equals: The cancer cell hierarchy
Ichim, C. V., & Wells, R. A. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600733325 · Cited by 46
“In addition work from Weissman’s group suggest b-catenin is capable of increasing the in vitro self-renewal capacity of non-leukemic granulocytemacrophage progenitors and that the granulocytemacrophage progenitors in the blast crisis phase of chronic myelogenous leukemia, which express nuclear b-catenin, have in vitro…”
BackgroundProstate stem cells: From development to cancer
Signoretti, S., & Loda, M. F. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.04.004 · Cited by 42
Translational Mini-Review Series on Vaccines: Peptide vaccines for myeloid leukaemias
Barrett, A. J., & Rezvani, K. (2007) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2007.03383.x · Cited by 40
Deregulated Notch and Wnt signaling activates early-stage myeloid regeneration pathways in leukemia
Kang, Y.-A., Pietras, E. M., & Passegue, E. A. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190787 · Cited by 45
Cancer as a reprogramming-like disease: Implications in tumor development and treatment
Castellanos‐Martín, A., Vicente‐Dueñas, C., Campos‐Sánchez, E., Cruz, J. J., García‐Criado, F. J., Cenador, M. B. G., Lazo, P. A., Pérez‐Losada, J., & Sánchez-García, I. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.001 · Cited by 41
Pizzatti, L., Panis, C., Lemos, G. F., da Rocha, M. M., Cecchini, R., Souza, G. H. M. F., & Abdelhay, E. S. F. W. (2012) · PROTEOMICS · doi:10.1002/pmic.201200066 · Cited by 46
“Once within the BM, CML stem cells utilize the survival/self-renewal pathways that are active in normal haematopoietic stem cells, such as the Wnt/beta-catenin and Hedgehog activation pathways [6, 9].”
BackgroundWill, B., & Steidl, U. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.06.006 · Cited by 39
In vitro biology of human myeloid leukemia
Mayani, H., Figueroa, E. F., & Chávez‐González, A. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.11.011 · Cited by 45
“Numerous lines of evidence, both in murine and human systems, indicate that leukemia stem cells may arise from transformed progenitor cells [44–47], which acquire functional capabilities, such as the ability to selfrenew, that are not usually seen in normal progenitors, but are key features of stem cells.”
BackgroundIs Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer
Trop-Steinberg, S., & Azar, Y. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.06.007 · Cited by 45
“The role of Myc activity in blastic transformation is also strengthened by the fact that Myc is a known beta-catenin target gene, which has been shown to be activated in blast crisis patients.(108,109) Therefore, overexpression of Myc could play a critical role in BCR/ABL1 upregulation and in blast aggressiveness acqu…”
Goldman, J. M. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.08.001 · Cited by 38
Chronic Myeloid Leukemia: Overview of New Agents and Comparative Analysis
Jain, P., Kantarjian, H. M., & Cortes, J. E. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0234-8 · Cited by 38
The role of microRNAs in hematopoietic stem cell and leukemic stem cell function
Chung, S. S., Hu, W., & Park, C. Y. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410772 · Cited by 42
“…epigenetic events accumulating in HSCs or immature hematopoietic progenitors, culminating in the aberrant acquisition of stem-cell-like characteristics, including self-renewal, in progenitor cells that typically do not possess the ability to self-renew [Jamieson et al. 2004; Passegue et al. 2003].”
BackgroundCancer stem cell subsets and their relationships
Liu, H., Chen, C., Yang, H., Pan, Y., & Zhang, X. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-50 · Cited by 41
“[75] reported that during blast-crisis of chronic myelogenous leukemia (CML), granulocyte-macrophage progenitors acquired much stronger self-renewal property due to the activation of Wnt/b-catenin pathway, and expressed BCR-ABL protein and expanded imatinib-resistant CML.”
BackgroundBenoit, Y. D., Guezguez, B., Boyd, A. L., & Bhatia, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2491 · Cited by 44
“Examples of the participation of Wnt/GSK‐3 signaling in CSC development include cases of BCR‐ABL chronic myeloid leukemia (CML) (14, 15) presenting an aberrant non‐functional form of GSK‐3 showing neoplastic progression towards an aggressive”
BackgroundO'Brien, S. M., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., DeAngelo, D. J., Devine, S. M., Fathi, A. T., Gotlib, J. R., Jagasia, M., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0009 · Cited by 41
Benzene and its effects on cell signaling pathways related to hematopoiesis and leukemia
Lu, P. C. W., Shahbaz, S., & Winn, L. M. (2020) · Journal of Applied Toxicology · doi:10.1002/jat.3961 · Cited by 43
“A hallmark of CML is the presence of the Philadelphia chromosome due to chromosomal translocation, which produces the fusion product BCR-ABL1.”
BackgroundInfluentialWnt Signaling in Leukemia and Its Bone Marrow Microenvironment
Ruan, Y., Kim, H. N., Ogana, H. A. N., & Kim, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176247 · Cited by 46
“It has been shown that the enhancement of self-renewal activity is associated with the activation of the Wnt–β-catenin pathway [55].”
BackgroundA challenge for regenerative medicine: Proper genetic programming, not cellular mimicry
Rizzino, A. (2007) · Developmental Dynamics · doi:10.1002/dvdy.21285 · Cited by 38
Zhao, R. C., Zhu, Y., & Shi, Y. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.04.008 · Cited by 43
“Leukemic granulocyte-macrophage progenitors have been shown to be able to self-renew and cause a blast crisis in some patientswith chronicmyeloid leukemia through aberrant activation of the Wnt/β-catenin signaling pathway (Jamieson et al., 2004).”
BackgroundStem cell‐based therapy in gastroenterology and hepatology
Piscaglia, A. C., Novi, M., Campanale, M., & Gasbarrini, A. (2008) · Minimally Invasive Therapy & Allied Technologies · doi:10.1080/13645700801969980 · Cited by 42
Nygren, M. K., Døsen, G., Stubberud, H., Wälchli, S., Munthe, E., & Rian, E. (2008) · Experimental Hematology · doi:10.1016/j.exphem.2008.10.007 · Cited by 38
“In chronic myelogenous leukemia, b-catenin is activated and enhances the self-renewal capacity and leukemic potential of the progenitor cells [13].”
BackgroundLai, Y., Tsai, J.-C., Tseng, Y.-T., Wu, M.-S., Liu, W.-S., Lam, H.-I., Yu, J.-H., Nozell, S. E., & Benveniste, E. N. (2017) · Oncotarget · doi:10.18632/oncotarget.14949 · Cited by 44
“A stemloid came from a proliferative cancer stem cell or an immortalized proliferating cell could produce the same outcome [12, 13].”
BackgroundIntegrin α6 (CD49f), The Microenvironment and Cancer Stem Cells
Ordóñez, G. D. B., Czarnowski, D., Parsons, T. M., Madlambayan, G. J., & Villa-Diaz, L. G. (2018) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x13666181002151330 · Cited by 37
Blastic phase of chronic myelogenous leukemia
Karbasian‐Esfahani, M., Morris, E., Dutcher, J. P., & Wiernik, P. H. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0012-y · Cited by 37
“The enhanced leukemic potential of CML granulocyte macrophage progenitor cells has also been attributed to the activation of -catenin, resulting in these progenitor cells acquiring the capacity of self-renewal [ 18 ].”
BackgroundOld disease, new culprit: Tumor stem cells in cancer
Lee, J. T., & Herlyn, M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21252 · Cited by 43
“Follow-up studies support the notion that committed progenitors are indeed leukemic stem cells, likely due to additional mutations that confer self-renewal properties to the progenitor cells (Huntly et al., 2004; Jamieson et al., 2004).”
BackgroundLinking miRNA Regulation to BCR-ABL Expression: The Next Dimension
Faber, J., Gregory, R. I., & Armstrong, S. A. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.013 · Cited by 37
“Also, activation of the Wnt pathway in myeloid progenitor cells accompanies CML progression (Jamieson et al., 2004).”
BackgroundRao, A. S., Kremenevskaja, N., von Wasielewski, R., Jakubcakova, V., Kant, S., Resch, J., & Brabant, G. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1381 · Cited by 37
RetractedHematopoietic stem cells and retroviral infection
Banerjee, P., Crawford, L. B., Samuelson, E., & Feuer, G. (2010) · Retrovirology · doi:10.1186/1742-4690-7-8 · Cited by 45
Differential Destruction of Stem Cells: Implications for Targeted Cancer Stem Cell Therapy
Sehl, M. E., Sinsheimer, J. S., Zhou, H., & Lange, K. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2070 · Cited by 38
“Cancer stem cells are involved in disease pathogenesis and progression as well as in relapse and resistance to therapy (8, 9, 14, 15).”
BackgroundFragoso, R., & Barata, J. T. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.05.005 · Cited by 38
“LSCs have now also been described in other types of leukemia, such as B- and T-cell acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) (Cox et al., 2007; Jamieson et al., 2004; Martelli et al., 2014; Nishida et al., 2009; le Viseur et al., 2008).”
BackgroundLeukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPα
Ferrari‐Amorotti, G., Keeshan, K., Zattoni, M., Guerzoni, C., Iotti, G., Cattelani, S., Donato, N. J., & Calabretta, B. (2006) · Blood · doi:10.1182/blood-2006-01-011833 · Cited by 38
“A plausible model predicts that increased BCR/ABL expression during disease progression (15-17) promotes secondary genetic and epigenetic changes essential for the expansion of clones with increasingly malignant characteristics (17, 18).”
BackgroundReins, J., Mossner, M., Neumann, M., Platzbecker, U., Schumann, C., Thiel, E., & Hofmann, W.-K. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.013 · Cited by 38
Skorski, T. (2011) · Leukemia & Lymphoma · doi:10.3109/10428194.2010.546912 · Cited by 36
“In the more aggressive blast phase (CML-BP), leukemia progenitors (LCMP, LGMP) gain self-renewal capability [2] and are therefore LSC candidates.”
BackgroundHuntly, B. J. P., & Gilliland, D. G. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.005 · Cited by 38
The Chronic Myeloid Leukemia Stem Cell
Nicholson, E., & Holyoake, T. L. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.037 · Cited by 42
Biological Principles for Ex Vivo Adult Stem Cell Expansion
Paré, J., & Sherley, J. L. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)73005-2 · Cited by 43
Good cells gone bad: the cellular origins of cancer
Wang, J. C. Y. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.001 · Cited by 36
Comparative Proteome Profiling and Functional Analysis of Chronic Myelogenous Leukemia Cell Lines
Fontana, S., Alessandro, R., Barranca, M., Giordano, M., Corrado, C., Zanella‐Cléon, I., Becchi, M., Kohn, E. C., & Leo, G. D. (2007) · Journal of Proteome Research · doi:10.1021/pr0704128 · Cited by 36
Kanodia, S., Wieder, E., Lu, S., Talpaz, M., Alatrash, G., Clise-Dwyer, K., & Molldrem, J. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011770 · Cited by 39
“In patients with blast crisis CML, CFUBM may be the reservoir of leukemia stem cells (LSCs) [10].”
BackgroundRosu‐Myles, M., Taylor, B. J., & Wolff, L. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2006.11.005 · Cited by 41
Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Ichim, C. V. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0159 · Cited by 35
Activation of β-catenin signalling leads to temporomandibular joint defects
Wang, M., Li, S., Xie, W., Shen, J., Im, H.-J., Holz, J. D., Wang, M., Diekwisch, T., & Chen, D. (2014) · European Cells and Materials · doi:10.22203/ecm.v028a15 · Cited by 35
“The potential mechanisms for β-catemn activation in patients with TMJ OA may include activating mutations of the β-catenin gene (Morin et al., 1997; Simon et al., 2005; Jamieson et al., 2004; Derksen et al., 2004), mechanical loading (Hens et al.”
BackgroundBlacking, T., Waterfall, M., & Argyle, D. J. (2011) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2011.02.004 · Cited by 40
Beer, P. A., Knapp, D. J. H. F., Miller, P. H., Kannan, N., Sloma, I., Heel, K., Babovic, S., Bulaeva, E., Rabu, G. M., Terry, J., et al. (2014) · Blood · doi:10.1182/blood-2014-06-581173 · Cited by 35
“Potential explanations for these differences include the supraphysiological STAT5 activation resulting from g-retroviral–mediated BCR-ABL1 expression, which drives erythroid differentiation in the transduced cells(27,49,50) and fails to mimic the differentiation stage-associated changes (decreases) in BCR-ABL1expressi…”
BackgroundEndogenous retrovirus induces leukemia in a xenograft mouse model for primary myelofibrosis
Triviai, I., Ziegler, M., Bergholz, U., Oler, A. J., Stübig, T., Prassolov, V., Fehse, B., Kozak, C. A., Kröger, N. M., & Stocking, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401215111 · Cited by 34
“In vivo and in vitro studies have demonstrated that the chronic myeloid leukemia neoplastic stem cell maintaining the chronic disease shares many characteristics of normal HSC; furthermore, their downstream progenitors are the likely targets of transformation events that generate the malignant clone in the acute phase…”
BackgroundZhou, J., Wang, H., Cannon, V. S., Wolcott, K., Song, H., & Yates, C. C. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-112 · Cited by 34
“Although there is no known function for CD133, it is expressed by developing epithelial cells and is rapidly down-regulated upon differentiation [13-16].”
BackgroundEl-Badawy, A., Ghoneim, M. A., Gabr, M. M., Salah, R. A., Mohamed, I. K., Amer, M., & El‐Badri, N. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0709-9 · Cited by 35
“In addition, committed progenitors can acquire self-renewal ability and function as CSCs [14, 15].”
BackgroundGlycogen synthase kinase‐3 and alternative splicing
Liu, X., & Klein, P. S. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1501 · Cited by 41
Hematopoietic stem cell biology: too much of a Wnt thing
Trowbridge, J. J., Moon, R. T., & Bhatia, M. (2006) · Nature Immunology · doi:10.1038/ni1006-1021 · Cited by 35
Prognostic significance of β‐catenin and topoisomerase IIα in de novo acute myeloid leukemia
Chen, C., Gau, J., You, J., Lee, K., Yu, Y., Lu, C., Lin, J., Lan, C., Lo, W., Liu, J. M., et al. (2008) · American Journal of Hematology · doi:10.1002/ajh.21334 · Cited by 34
“Jamieson et al.[32] have shown that aberrant activation of the Wnt/b-catenin pathway results in enhanced self-renewal capability in granulocyte-macrophage progenitors of blast-crisis CML.”
BackgroundBmi1 reprograms CML B-lymphoid progenitors to become B-ALL–initiating cells
Sengupta, A., Ficker, A. M., Dunn, S. K., Madhu, M., & Cancelas, J. A. (2011) · Blood · doi:10.1182/blood-2011-06-359232 · Cited by 37
STAT transcription factors in normal and cancer stem cells
Dorritie, K. A., Redner, R. L., & Johnson, D. E. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.05.004 · Cited by 38
Chronic Myeloid Leukemia: Origin, Development, Response to Therapy, and Relapse
Dingli, D., Traulsen, A., & Pacheco, J. M. (2008) · Clinical Leukemia · doi:10.3816/clk.2008.n.017 · Cited by 36
Li, S., & Li, D. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00108.x · Cited by 36
“For example, granulocyte-macrophage progenitors have been identified as potential leukaemic stem cells for human CML myeloid blast crisis, and -catenin that is involved in self-renewal of normal HSCs [34, 35] is also activated in granulocyte-macrophage progenitors [36], which appear to have acquired the potential for…”
BackgroundCancer stem cells: controversies in multiple myeloma
Brennan, S. K., & Matsui, W. H. (2009) · Journal of Molecular Medicine · doi:10.1007/s00109-009-0531-7 · Cited by 37
“In chronic myeloid leukemia, studies have suggested that the transition from chronic phase to blast crisis is mediated by changes in Wnt/β-catenin signaling [55].”
BackgroundMcCune, J. M., & Weissman, I. L. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.10.003 · Cited by 35
Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy
Borlongan, M. C., Saha, D., & Wang, H. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10639-6 · Cited by 41
Functional Characterization of a Small-Molecule Inhibitor of the DKK1-LRP6 Interaction
Iozzi, S., Remelli, R., Lelli, B., Diamanti, D., Pileri, S., Bracci, L., Roncarati, R., Caricasole, A., & Bernocco, S. (2012) · ISRN Molecular Biology · doi:10.5402/2012/823875 · Cited by 36
Janssen, J. J. W. M., Deenik, W., Smolders, K., van Kuijk, B. J., Pouwels, W., Kelder, A., Cornelissen, J. J., Schuurhuis, G. J., & Ossenkoppele, G. J. (2011) · Leukemia · doi:10.1038/leu.2011.347 · Cited by 34
Roos, J., Grösch, S., Werz, O., Schröder, P., Ziegler, S., Fulda, S., Paulus, P., Urbschat, A., Kuhn, B. R., Maucher, I. V., et al. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.001 · Cited by 37
KIT regulates tyrosine phosphorylation and nuclear localization of β-catenin in mast cell leukemia
Kajiguchi, T., Lee, S., Lee, M.-J., Trepel, J. B., & Neckers, L. (2008) · Leukemia Research · doi:10.1016/j.leukres.2007.08.023 · Cited by 33
Hamuro, J., Ueno, M., Toda, M., Sotozono, C., Montoya, M. M., & Kinoshita, S. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19771 · Cited by 34
Styczyński, J., & Drewa, T. A. (2007) · Acta Biochimica Polonica · doi:10.18388/abp.2007_3140 · Cited by 34
Kiyota, M., Kuroda, J., Yamamoto‐Sugitani, M., Shimura, Y., Nakayama, R., Nagoshi, H., Mizutani, S., Chinen, Y., Sasaki, N., Sakamoto, N., et al. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0882-y · Cited by 36
Buckley, N. E., & Mullan, P. B. (2012) · Stem Cell Reviews and Reports · doi:10.1007/s12015-012-9354-y · Cited by 32
“However, when the disease progresses to the more acute and advanced stage of blast crisis, it has been demonstrated that a subsequent genetic event occurring in the downstream granulocytemacrophage progenitor gives rise to the leukaemic stem cell which drives this stage of the disease [72].”
BackgroundPizzatti, L., Binato, R., Cofré, J., Gomes, B. E., Dobbin, J., Haussmann, M. E., D'Azambuja, D., Bouzas, L. F., & Abdelhay, E. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20722 · Cited by 32
“Despite the high levels of nuclear b-catenin reported in CML blastic phase (Jamienson et al., 2004) our supershift experiments with a b-catenin antibody did not detect any specific complex with the SUZ12 promoter in CML cells.”
BackgroundCancer Stem Cells in Squamous Cell Carcinoma
Jian, Z., Strait, A. A., Jimeno, A., & Wang, X. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.07.033 · Cited by 35
“CSCs can be derived from SCs (Morris et al., 1986) or from nonstem cells that acquire the capacity to self-renew (Jamieson et al., 2004).”
BackgroundPRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells
Hu, T., Morita, K., Hill, M. C., Jiang, Y., Kitano, A., Saito, Y., Wang, F., Mao, X., Hoegenauer, K. A., Morishita, K., et al. (2019) · Blood · doi:10.1182/blood.2018888255 · Cited by 33
Signaling Pathways in Leukemic Stem Cells
Gurska, L. M., Ames, K. T., & Gritsman, K. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7342-8_1 · Cited by 38
Searching for leukemia stem cells—Not yet the end of the road?
Jordan, C. T. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.09.010 · Cited by 33
Cairo, M. S., Jordan, C. T., Maley, C. C., Chao, C., Melnick, A. M., Armstrong, S. A., Shlomchik, W. D., Molldrem, J., Ferrone, S., Mackall, C. L., et al. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.03.002 · Cited by 35
Two types of precursor cells in a multipotential hematopoietic cell line
Ye, Z.-J., Kluger, Y., Lian, Z., & Weissman, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509314102 · Cited by 32
Molecular pathways to CML stem cells
Rice, K. N., & Jamieson, C. H. M. (2010) · International Journal of Hematology · doi:10.1007/s12185-010-0615-8 · Cited by 31
“In blast crisis CML, the LSC, which resemble granulocyte-macrophage progenitor cells (GMP) have aberrant activation of b-catenin via the canonical Wnt signaling pathway [ 15 ].”
BackgroundInfluentialWeiss, C. N., & Ito, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036183 · Cited by 37
“Of course, accumulated DNA damage is essential in the development of malignancies, and DNA damage accumulated in HSCs and progenitors is responsible, in part, for hematological malignancies [9,10].”
BackgroundMelo, J. V., & Ross, D. M. (2011) · Hematology · doi:10.1182/asheducation-2011.1.136 · Cited by 32
Is going for cure in chronic myeloid leukemia possible and justifiable?
Mahon, F. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.122.3798214 · Cited by 34
Preferential hypermethylation of the Dickkopf‐1 promoter in core‐binding factor leukaemia
Suzuki, R., Onizuka, M., Kojima, M., Shimada, M., Fukagawa, S., Tsuboi, K., Kobayashi, H., Shintani, A., Ogawa, Y., Kawada, H., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06702.x · Cited by 32
“The Wnt/b-catenin pathway can promote the self-renewal of normal haematopoietic stem cells and leukaemic progenitors (Reya et al, 2003; Jamieson et al, 2004).”
BackgroundCimato, T. R., Furlage, R. L., Conway, A. N., & Wallace, P. K. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21354 · Cited by 35
“(7), and myelodysplastic syndromes (8).”
Fioretos, T. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch8 · Cited by 31
Zhang, B., Zhao, D., Chen, F., Frankhouser, D. E., Wang, H., Pathak, K. V., Dong, L., Torres, A., Garcia‐Mansfield, K., Zhang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41167-z · Cited by 34
“…immunophenotypically consistent with LSKs and GMPs, and previous reports suggested that LSCs may also reside in the GMP fraction of CML models 38 , we conducted transplant experiments to identify which of these fractions from miR-142 − / − BCR-ABL or miR-142 +/+ BCR-ABL mice were more…”
Ahmed, W. B., & Etten, R. A. V. (2013) · Hematology · doi:10.1182/asheducation-2013.1.189 · Cited by 31
Zheng, Q., Peng, X., & Yu, H. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.11.011 · Cited by 30
MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus
Bulaeva, E., Pellacani, D., Nakamichi, N., Hammond, C. A., Beer, P. A., Lorzadeh, A., Moksa, M., Carles, A., Bilenky, M., Lefort, S., et al. (2020) · Blood · doi:10.1182/blood.2020006374 · Cited by 34
Metadata
- Authors
- Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., Sawyers, C. L., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- University of Toronto (CA)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-08-12
- Volume
- 351
- Issue
- 7
- Pages
- 657-667
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2012962381
- Cited by
- 1,485
- References
- 58
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 19 · 2023: 36 · 2022: 27 · 2021: 33 · 2020: 40 · 2019: 37 · 2018: 40 · 2017: 53 · 2016: 80 · 2015: 74 · 2014: 81 · 2013: 95 · 2012: 114
- FWCI
- 55.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K23HL04409, K23HL004409)
- National Cancer Institute (2PO1CA49605, CA 86017, CA 55209, R01CA086017, P01CA049605)
- National Institute of Allergy and Infectious Diseases (5 T32 AI07290, T32AI007290)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, blast crisis, leukemia stem cells, CFU-GM, β-catenin signaling, BCR-ABL, self-renewal, Axin, imatinib resistance, hematopoietic stem cells, myeloid progenitor cells
- MeSH terms
- Imatinib Mesylate, Adult, Aged, Antineoplastic Agents, Benzamides, Blast Crisis, Colony-Forming Units Assay, Cytoskeletal Proteins, DNA-Binding Proteins, Female, Granulocytes, Hematopoietic Stem Cells, Humans, Macrophages, Male, Middle Aged, Piperazines, Pyrimidines, RNA, Neoplasm, Transcription Factors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Trans-Activators, Fusion Proteins, bcr-abl, Microscopy, Confocal, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, beta Catenin, Lymphoid Enhancer-Binding Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.